Zura Bio Ltd Ordinary Shares - Class A ZURA
News
ZURA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zura Bio Limited
ZURA Investors Have Opportunity to Join Zura Bio Limited Fraud Investigation with SBS Law
Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $1.24
- Day Range
- $1.16–1.53
- 52-Week Range
- $0.93–7.44
- Bid/Ask
- $1.38 / $1.40
- Shares Outstanding
- 96.33M
- Market Cap
- $135.34M
- Volume/Avg
- 17M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 40
- Website
- https://www.zurabio.com
Valuation
Metric | ZURA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ZURA |
|---|---|
Quick Ratio | 11.06 |
Current Ratio | 11.29 |
Interest Coverage | — |
Quick Ratio
ZURA
Profitability
Metric | ZURA |
|---|---|
Return on Assets (Normalized) | −42.67% |
Return on Equity (Normalized) | −47.63% |
Return on Invested Capital (Normalized) | −50.84% |
Return on Assets
ZURA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|^T@@GK? | LOCK|!NX%% | $139B | |||
| Moderna Inc MRNA | LOCK|#CB%!W | LOCK|mP% | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!!!x><@ | LOCK|d$%% | $95B | |||
| argenx SE ADR ARGX | LOCK|<FTl<& | LOCK|B$ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%X$XPY | LOCK|>W! | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|B&dK^NjW | LOCK|fmlG@ | $31B | |||
| Incyte Corp INCY | LOCK|>>Szl^ | LOCK|wS | $25B | |||
| BioNTech SE ADR BNTX | LOCK|>&x<WH! | LOCK|$Mp | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|??^m&s! | LOCK|%tRMV | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?s?@H#r | LOCK|Q>x | $16B |
United States